Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model

Journal of Gene Medicine

Volumn 5, Issue 5, 2003, Pages 377-385

  Desaknai, Szilvia ^a   Lumniczky, Katalin ^a   Esik, Olga ^b   Hamada, Hirofumi ^c   Safrany, Geza ^a  

^a National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Ganciclovir; GDEPT; Glioma; Irradiation

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; GANCICLOVIR; THYMIDINE KINASE; URACIL PHOSPHORIBOSYLTRANSFERASE; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GLIOMA; GLIOMA CELL; IN VITRO STUDY; INTRACRANIAL TUMOR; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SENSITIZATION; SUBCUTANEOUS TISSUE TUMOR; SUICIDE GENE THERAPY; TUMOR LOCALIZATION; ADENOVIRUS; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CELL LINE; DISEASE COURSE; DOSE RESPONSE; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; TIME; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CELL LINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOMA; MICE; MICE, INBRED C57BL; RADIOTHERAPY; TIME FACTORS;

EID: 1542781699     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.357     Document Type: Article

References (31)

1. Shoenberg BS, Walker MD (eds). Oncology of the Nervous System. Martinus Nijhoff: Boston, 1993; 1-30.
2. Mahaley MS, Mettlin C, Natarjan N, et al. National survey of patterns of care for brain-tumor patients. J Neurosurg 1989; 71: 826-836.
3. Inaba M, Sawaa H, Sadata A, Hamada H. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction, Jpn d Cancer Res 1999; 90: 349-354.
4. Aghi M, Hochberg F, Breakfield X. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000; 2: 148-164.
5. Aghi M, Kramm CM, Chao T, et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
6. Takamiya Y, Short MP, Ezzedine ZD, et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type-1 thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493-503.
7. Maron A, Gustin T, Le Roux A, et al. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Long-term follow-up by magnetic resonance imaging. Gene Ther 1996; 3: 315-322.
8. Kanai F, Kawakami T, Hamada H, et al. Adenovirus mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
9. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002; 62: 773-780.
10. Buchholz DJ, Lepek KJ, Rich TA, et al. 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys 1995; 32: 1053-1058.
11. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radio sensitization on DNA directed effects. Int J Radiat Oncol Biol Phys 1994; 29: 519-523.
12. Hamstra DA, Rice DJ, Pu A, et al. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat Res 1999; 152: 499-507.
13. Kievit E, Nyati MK, Ng E. Yeast cytosine deaminase improves radio sensitization and bystander effect by 5-fluorocytosine of human colorectal xenografts. Cancer Res 2000; 60: 6649-6655.
14. LumniczkyK, Désaknai Sz, Mangel L, et al. Local tumor irradiation augments the anti-tumor effect of cytokine producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002; 9: 44-52.
15. Désaknai S, Lumniczky K, Hidvégi EJ, et al. Brain tumor treatment with IL-2 and IL-12 producing autologous cancer cell vaccines. Adv Exp Med Biol 2001; 495: 369-372.
16. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing full-length virus genome. Proc Natl Acad Sci U S A 1996; 93: 1320-1324.
17. Chen SH, Shine HD, Goodman JC, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994; 91: 3054-3057.
18. Izquiredo M, Cortes M, Felipe P, et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 1995; 2: 66-69.
19. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 2: 195-203.
20. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 10: 2325-2335.
21. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9: 2595-2604.
22. Chang JW, Lee H, Kim E, et al. Combined antitumor effects of ah adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. Neurosurgery 2000; 47: 931-938.
23. Moriuchi S, Wolfe D, Tamura M, et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002; 9: 584-591.
24. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
25. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene; significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91: 8302-8306.
26. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
27. Freeman SM, Abboud CN, Whatenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
28. Gabel M, Kim JH, Kolozsvary A, et al. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat Oncol Biol Phys 1998; 41: 883-887.
29. Kim JH, Kolozsvary A, Rogulski K, et al. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer J Sci Am 1998; 4: 364-369.
30. Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-8750.
31. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001; 61: 5336-5339.